While various medicines are produced in South Africa, the active pharmaceutical ingredients going into these medicines are mostly still imported. Catherine Tomlinson reports on a local company that is trying to change that – starting with active pharmaceutical ingredients for tuberculosis and COVID-19 medicines.
The period covered by South Africa’s National Strategic Plan (NSP) for HIV, TB, and STIs 2017 – 2022 will soon come to an end. Against the backdrop of another World TB Day, Tiyese Jeranji asked several local tuberculosis experts what they think the TB priorities should be as South Africa develops an NSP for the next five years.
Long-acting injections have been successfully used as contraception and more recently HIV prevention. Now researchers are exploring whether similar long-acting injections could be used for the prevention and treatment of tuberculosis. Tiyese Jeranji reports.
Dr Jennifer Furin has fought drug-resistant tuberculosis (TB) since 1995, when she worked as a student in a poverty-stricken suburb in Lima, Peru. Since then she has roamed the world, treating TB and HIV patients in under-resourced countries, including Haiti, Russia, Tajikistan, Bangladesh, eSwatini, Lesotho, and South Africa. Biénne Huisman chatted to Furin about her life working in TB and what it means to see things from the perspective of people living with TB.
For healthcare, a post-pandemic human rights-focused budget would have allocated funding specifically for backlogs in access to health services from the past two years, as well as tackling the present inequities in access to healthcare that characterise the public health system. Tshidi Lencoasa, Khanyisa Mapipa, and Julia Chaskalson argue that this year’s budget does not do enough to enable government to realise people’s fundamental human right to access healthcare.
Broadly neutralising antibodies (bnAbs) are one of the most active and exciting areas in HIV research. Last year Spotlight reported on a “proof of concept” study showing that a specific bnAb can successfully prevent infection with certain strains of HIV. Now, we also have intriguing findings suggesting that bnAbs may have a role to play in the treatment of HIV in children. Elri Voigt reports.
HIV and ageing were one of the hot topics at the recently held Conference on Retroviruses and Opportunistic Infections. Elri Voigt reports.
While there are nine experimental tuberculosis (TB) vaccines in advanced trials, the vaccine pipeline beyond those nine prospects is relatively depleted. Adele Baleta reports on this and much more from the virtual Global TB Vaccine Forum held last week.
An innovative new technology that allows women to collect their own samples for HPV testing, rather than having the sample taken by a healthcare worker, was recently tested in the Eastern Cape. Elri Voigt spoke to local experts about the study and what such a self-collected test might mean for cervical cancer detection in South Africa.
As was the case in the rest of the country, the COVID-19 pandemic dealt a severe blow to the tuberculosis (TB) response in the Free State. Refilwe Mochoari gathered the available numbers and asked the province’s health department about their plans to get the TB response back on track.
COVID-19 will continue to dominate headlines in 2022, but from National Health Insurance to the availability of a new HIV prevention injection, it will also be an important year for other areas of health service delivery and for health system governance and reforms. Here is Spotlight’s pick of the top ten issues to keep an eye on.
It wasn’t rocket science when we predicted at the start of 2021 that South Africa’s biggest challenge this year would be to get COVID-19 shots into as many arms as possible. But the way it has played out with multiple setbacks and scrambling problem-solving is not something anyone could have predicted. In fewer than a thousand words, Spotlight editor Marcus Low takes a look back at a tumultuous year in health in South Africa.
